CureVac develops vaccines in Waldner laboratories

The RNA people - The Tübingen-based company CureVac is developing a new class of drugs using messenger RNA, which is used as a messenger substance in the body. While DNA is virtually the source code of life and carries the genetic information of the body, the messenger molecule mRNA takes over specific instructions for the production of a protein from a gene.

CureVac has developed a nucleotide sequence library with which mRNA molecules can be assembled for specific therapeutic applications and are thus specially optimized for different indications. Using mRNA technology, the body can be directly provided with the information it needs to fight and cure diseases.

The technology and mRNA platform are suitable for rapid response to a viral outbreak such as the Corona Pandemic. CureVac is currently developing a vaccine against the SARS-CoV-2 virus based on mRNA technology.

Waldner is currently equipping the company CureVac with a new laboratory. Up to now, CureVac has also carried out research in Waldner laboratories (mc6 series). The new laboratory from the current SCALA product series has already been produced and is currently being installed at CureVac. The laboratory was planned by TEAMPLAN GmbH, Tübingen (Germany). From approx. mid-May, CureVac employees will then conduct research in the modern Waldner laboratory with an area of approx. 1,400 square metres.

Picture: Technologiepark Tübingen-Reutlingen GmbH, Copyright CureVac AG

To Top